Skip to main content
. 2004 Jan;13(1):240–254. doi: 10.1110/ps.03296404

Table 1.

The predicted binding site positions

OR segment position Alignment position Other GPCR GPCR amino acid
TM2 13 86 Human endothelin-1 receptor precursor (ET-A) Y:129
TM3 4 115 Rat muscarinic m1 receptor L:102
TM3 7 118 Rat muscarinic m1 receptor D:105
TM3 8 119 Rat muscarinic m3 receptor Y:148
TM3 11 122 Human dopamine D3 receptor C:114
TM3 12 123 Rat muscarinic m1 receptor N:110
TM3 15 126 Rat muscarinic m1 receptor V:113
TM3 16 127 NA
TM4 12 167 Bovine rhodopsin A:164
TM4 16 171 Human dopamine D2 receptor S:267
TM4 19 174 Rat muscarinic m3 receptor P:201
EL2-1 193 cholecystokinin type B (CCKB) receptor Q:204
EL2 2 196 cholecystokinin type B (CCKB) receptor H:207
TM5 2 214 Human α2A adrenergic receptor V:197
TM5 6 218 Human α2A adrenergic receptor C:201
TM5 9 221 Human α2A adrenergic receptor S:204
TM5 10 222 Rat 5HT2A serotonin receptor F:243
TM6 12 288 Bovine rhodopsin F:261
TM6 15 291 Rat type-1B angiotensin II receptor S:252
TM7 5 321 Human neurokinin-1 (substance P) receptor I:290
TM7 6 322 Human dopamine D3 receptor T:369
TM7 9 325 Rat muscarinic m1 receptor C:407

The 22 predicted binding site positions in OR proteins with their numbering within the various protein segments and the alignment. The “other GPCR” column lists non-OR GPCRs in which the corresponding residue was linked to ligand binding, and the “GPCR amino acid” column gives the enumeration of this residue in the original protein sequence. NA indicates that no functional residue in a non-ORGPCR was found to align against the position. Information regarding functional residues was derived from the tiny GRAP mutant database (Edvardsen et al. 2002) via the GPCRDB graphical interface (Horn et al. 2001), and from (Baldwin 1994; Ji et al. 1995; Silvente-Poirot and Wank 1996; Lu and Hulme 1999; Ballesteros et al. 2001; Shi and Javitch 2002), and was matched to the prediction using the alignment in Figure 2A.